Gemini Space Station Inc vs Twist Bioscience Corp — how do they compare? Gemini Space Station Inc trades at $4.45 (market cap $582.14M), while Twist Bioscience Corp trades at $157.96 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 17.7× Gemini Space Station Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Twist Bioscience Corp for 27 Days on average.
| GEMI | TWST | |
|---|---|---|
Market Cap | $582.14M | $10.32B |
Volume | 1,995,802 | 5,894,998 |
Sector | Financials | Health |
52-Week High | $25.41 | $205.00 |
52-Week Low | $3.54 | $25.45 |
Typical Hold Time | 14 Days | 27 Days |
Enterprise Value | $561.16M | $10.24B |
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.49, down 3.85% today, with a bearish technical signal despite oversold RSI readings. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$517 million. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits alleging securities violations.
The outlook remains challenged by persistent losses and negative cash flow from operations, offset by financing activities. Analyst consensus is mixed with a $5.33 price target (48% upside), but high business execution and regulatory risks warrant caution. The stock's valuation appears stretched given profitability concerns, making it speculative for risk-tolerant investors.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →